Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release.

UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections.

Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.

“This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,” said Binesh Chudgar, Intas Pharma’s chairman and managing director.

Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA.

With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.

“The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,” said Chrys Kokino, President, USA, Accord BioPharma.